A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
Summary
The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.
Timeline
- Start
- 2015-04
- Primary completion
- 2016-04
- Completion
- 2016-04
Outcome
Met primary endpoint
registry analysis (other test); Olumacostat Glasaretil Gel, Vehicle QD vs Olumacostat Glasaretil Gel, Vehicle BID vs Olumacostat Glasaretil Gel, 4.0% QD vs Olumacostat Glasaretil Gel, 7.5% QD vs Olumacostat Glasaretil Gel, 7.5% BID; p = 0.0006; Cochran-Mantel-Haenszel NCT02431052 ↗
registry analysis (other test); Olumacostat Glasaretil Gel, Vehicle QD vs Olumacostat Glasaretil Gel, Vehicle BID vs Olumacostat Glasaretil Gel, 4.0% QD vs Olumacostat Glasaretil Gel, 7.5% QD vs Olumacostat Glasaretil Gel, 7.5% BID; p = 0.0002; Cochran-Mantel-Haenszel NCT02431052 ↗
registry analysis (other test); Olumacostat Glasaretil Gel, Vehicle QD vs Olumacostat Glasaretil Gel, Vehicle BID vs Olumacostat Glasaretil Gel, 4.0% QD vs Olumacostat Glasaretil Gel, 7.5% QD vs Olumacostat Glasaretil Gel, 7.5% BID; p = 0.0055; Cochran-Mantel-Haenszel NCT02431052 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olumacostat Glasaretil | Small molecule | 4 % | Topical |
| Subject | Olumacostat Glasaretil | Small molecule | 7.5 % | Topical |